Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efecto de la vitamina B2 suministrada por el colon sobre la microbiota intestinal y los biomarcadores de salud relacionados en adultos mayores sanos

6 de noviembre de 2026 actualizado por: dsm-firmenich Switzerland AG

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

348

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Cork, Irlanda
        • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

50 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a BMI of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the investigational product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.

  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)

  3. Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.

  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).

  5. Is a smoker or vaper.

  6. Vegetarian or vegan.

  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).

  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.

  9. Has a currently active eating disorder.

  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.

  11. Is having a typical fibre intake >30 g fibre/day.

  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.

  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.

  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.

  15. Has a current or history of any gastrointestinal cancer

  16. Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).

  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).

  18. Have a current malignant disease or any concomitant end-stage organ disease.

  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.

  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).

  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Low dose

Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Experimental: Mid dose

Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Experimental: high dose

Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Comparador de placebos: Placebo

One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Faecal microbial composition
Periodo de tiempo: from baseline to 12 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

from baseline to 12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Alpha diversity
Periodo de tiempo: from baseline to 12 weeks

Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

from baseline to 12 weeks
Beta diversity
Periodo de tiempo: week 0 to week 12

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Periodo de tiempo: from baseline to 12 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

from baseline to 12 weeks
Acetate, Propionate and Butyrate
Periodo de tiempo: baseline and week 12

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

baseline and week 12
Intestinal inflammation
Periodo de tiempo: from baseline to 12 weeks

Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

from baseline to 12 weeks
Intestinal barrier integrity
Periodo de tiempo: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Oxidative stress in blood
Periodo de tiempo: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Inflammatory status in blood
Periodo de tiempo: from baseline to 12 weeks

Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

from baseline to 12 weeks
Gastrointestinal symptoms
Periodo de tiempo: from baseline to 12 weeks

Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

from baseline to 12 weeks
health-related quality of life
Periodo de tiempo: from baseline to 12 weeks

Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12.

The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

from baseline to 12 weeks
Stool consistency
Periodo de tiempo: from baseline to 12 weeks

Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12).

Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

from baseline to 12 weeks
Stool frequency
Periodo de tiempo: from baseline to 12 weeks

Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

from baseline to 12 weeks
Systemic vitamin status
Periodo de tiempo: from baseline to 12 weeks

The concentration of B vitamins in blood at baseline

from baseline to 12 weeks
Faecal physiological pH and redox
Periodo de tiempo: from baseline to 12 weeks

Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

from baseline to 12 weeks
Faecal microbial composition at week 4
Periodo de tiempo: from baseline to 4 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

from baseline to 4 weeks
Alpha diversity at week 4
Periodo de tiempo: baseline to Week 4.

Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

baseline to Week 4.
Beta diversity at week 4
Periodo de tiempo: week 0 to week 4

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

week 0 to week 4
Microbial metabolites at week 4
Periodo de tiempo: from baseline to 4 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Periodo de tiempo: week 0 to week 4

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

week 0 to week 4

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Skin barrier integrity
Periodo de tiempo: from baseline to 12 weeks

Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

from baseline to 12 weeks
Skin hydration
Periodo de tiempo: from baseline to 12 weeks

Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

from baseline to 12 weeks
Objective skin-health
Periodo de tiempo: from baseline to 12 weeks

Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

from baseline to 12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Prof Timothy Dinan, Cork University Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de diciembre de 2022

Finalización primaria (Actual)

6 de julio de 2023

Finalización del estudio (Actual)

6 de julio de 2023

Fechas de registro del estudio

Enviado por primera vez

16 de febrero de 2023

Primero enviado que cumplió con los criterios de control de calidad

27 de marzo de 2023

Publicado por primera vez (Actual)

7 de abril de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de septiembre de 2023

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir